Targeting the porcine immune system-Particulate vaccines in the 21st century

Developmental and Comparative Immunology

Volumn 33, Issue 3, 2009, Pages 394-409

  McCullough, Kenneth C ^a   Summerfield, Artur ^a  

^a INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

Author keywords

Dendritic cells; Particulate vaccines receptor ligands; Vaccine targeting

Indexed keywords

GLYCOSAMINOGLYCAN; HEPARAN SULFATE; INTEGRIN; PARTICULATE VACCINE; PROLACTIN; PSEUDORABIES VACCINE; SYNTHETIC VACCINE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VACCINE; VACCINIA VACCINE; VIRUS VACCINE;

ADENOVIRUS; ANIMAL TISSUE; ARTICLE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; INNATE IMMUNITY; NONHUMAN; PARTICULATE MATTER; POXVIRUS; PRIORITY JOURNAL; PROTEIN TARGETING; PSEUDORABIES HERPETOVIRUS; VACCINATION; VACCINIA VIRUS; VIRUS CARRIER; VIRUS RECOMBINANT;

MURINAE; SUS;

EID: 57149085255     PISSN: 0145305X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dci.2008.07.015     Document Type: Article

References (234)

1. Janeway C. Immunogenicity signals 1,2,3... and 0. Immunol Today 10 (1989) 283-286
2. Fearon D. Happy coupling: recruiting both antigen and effector function. Nat Biotechnol 15 (1997) 618-619
3. Summerfield A, McCullough KC, editors. The porcine dendritic cell, Developmental and Comparative Immunology 2009;33:299-309.
4. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
5. MacPherson G., Kushnir N., and Wykes M. Dendritic cells, B cells and the regulation of antibody synthesis. Immunol Rev 172 (1999) 325-334
6. Jego G., Pascual V., Palucka A.K., and Banchereau J. Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun 8 (2005) 124-139
7. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 111 (2002) 927-930
8. Uenishi H, Shinkai H, editors. Porcine TLR: a front line of pathogen monitoring and possible implication in disease resistance. Developmental and Comparative Immunology 2009;33:353-61.
9. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199 (2004) 227-250
10. Lanzavecchia A., and Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 290 (2000) 92-97
11. McCullough K.C., and Summerfield A. Basic concepts of immune response and defense development. ILAR J 46 (2005) 230-240
12. Wiedemann F., Link R., Pumpe K., Jacobshagen U., Schaefer H.E., Wiesmuller K.H., et al. Histopathological studies on the local reactions induced by complete Freund's adjuvant (CFA), bacterial lipopolysaccharide (LPS), and synthetic lipopeptide (P3C) conjugates. J Pathol 164 (1991) 265-271
13. BenMohamed L., Gras-Masse H., Tartar A., Daubersies P., Brahimi K., Bossus M., et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol 27 (1997) 1242-1253
14. Seth A., Yasutomi Y., Jacoby H., Callery J.C., Kaminsky S.M., Koff W.C., et al. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses 16 (2000) 337-343
15. Mahnke K., Guo M., Lee S., Sepulveda H., Swain S.L., Nussenzweig M., et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 151 (2000) 673-684
16. Sapinoro R., Maguire C.A., Burgess A., and Dewhurst S. Enhanced transduction of dendritic cells by FcgammaRI-targeted adenovirus vectors. J Gene Med 9 (2007) 1033-1045
17. Ulaeto D., and Hruby D.E. Uses of vaccinia virus in vaccine delivery. Curr Opin Biotechnol 5 (1994) 501-504
18. Boyle D.B., Coupar B.E., Parsonson I.M., Bagust T.J., and Both G.W. Responses of cattle, sheep and poultry to a recombinant vaccinia virus expressing a swine influenza haemagglutinin. Res Vet Sci 41 (1986) 40-44
19. Marchioli C.C., Yancey Jr. R.J., Petrovskis E.A., Timmins J.G., and Post L.E. Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells. J Virol 61 (1987) 3977-3982
20. Zheng Q., Chen D., Chen D., Bi Z., Cao R., Zhou B., et al. Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus Ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV). Virus Genes 35 (2007) 585-595
21. Tripathy D.N. Swinepox virus as a vaccine vector for swine pathogens. Adv Vet Med 41 (1999) 463-480
22. Winslow B.J., Cochran M.D., Holzenburg A., Sun J., Junker D.E., and Collisson E.W. Replication and expression of a swinepox virus vector delivering feline leukemia virus Gag and Env to cell lines of swine and feline origin. Virus Res 98 (2003) 1-15
23. Fachinger V., Schlapp T., Strube W., Schmeer N., and Saalmüller A. Poxvirus-induced immunostimulating effects on porcine leukocytes. J Virol 74 (2000) 7943-7951
24. Drillien R., Spehner D., Bohbot A., and Hanau D. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology 268 (2000) 471-481
25. Jenne L., Hauser C., Arrighi J.F., Saurat J.H., and Hügin A.W. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene Ther 7 (2000) 1575-1583
26. Nagorsen D., Panelli M., Dudley M.E., Finkelstein S.E., Rosenberg S.A., and Marincola F.M. Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells. Gene Ther 10 (2003) 1754-1765
27. Chahroudi A., Garber D.A., Reeves P., Liu L., Kalman D., and Feinberg M.B. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J Virol 80 (2006) 8469-8481
28. Yates N.L., and Alexander-Miller M.A. Vaccinia virus infection of mature dendritic cells results in activation of virus-specific naive CD8+ T cells: a potential mechanism for direct presentation. Virology 359 (2007) 349-361
29. Peeters B., Bienkowska-Szewczyk K., Hulst M., Gielkens A., and Kimman T. Biologically safe, non-transmissible pseudorabies virus vector vaccine protects pigs against both Aujeszky's disease and classical swine fever. J Gen Virol 78 (1997) 3311-3315
30. Mettenleiter T.C., Klupp B.G., Weiland F., and Visser N. Characterization of a quadruple glycoprotein-deleted pseudorabies virus mutant for use as a biologically safe live virus vaccine. J Gen Virol 75 (1994) 1723-1733
31. Iglesias G., Pijoan C., and Molitor T. Interactions of Pseudorabies virus with swine alveolar macrophages I: virus replication. Arch Virol 104 (1989) 107-115
32. Iglesias G., Pijoan C., and Molitor T. Interactions of pseudorabies virus with swine alveolar macrophages: effects of virus infection on cell functions. J Leukoc Biol 45 (1989) 410-415
33. Shibata I., Urono K., Samegai Y., Okada M., and Inaba Y. Replication of virulent and attenuated strains of Aujeszky's disease virus in swine alveolar macrophages. J Vet Med Sci 56 (1994) 465-468
34. Vincent I.E., Balmelli C., Meehan B., Allan G., Summerfield A., and McCullough K.C. Silencing of natural interferon producing cell activation by porcine circovirus type 2 DNA. Immunology 120 (2007) 47-56
35. Hammond J.M., and Johnson M.A. Porcine adenovirus as a delivery system for swine vaccines and immunotherapeutics. Vet J 169 (2005) 17-27
36. Grubman M.J. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Biologicals 33 (2005) 227-234
37. Sanchez O., Barrera M., Rodriguez M.P., Frias M.T., Figueroa N.E., Naranjo P., et al. Classical swine fever virus E2 glycoprotein antigen produced in adenovirally transduced PK-15 cells confers complete protection in pigs upon viral challenge. Vaccine 26 (2008) 988-997
38. Toledo J.R., Sanchez O., Montesino R., Farnos O., Rodriguez M.P., Alfonso P., et al. Highly protective E2-CSFV vaccine candidate produced in the mammary gland of adenoviral transduced goats. J Biotechnol 133 (2008) 370-376
39. Torres J.M., Alonso C., Ortega A., Mittal S., Graham F., and Enjuanes L. Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. J Virol 70 (1996) 3770-3780
40. Moraes M.P., Chinsangaram J., Brum M.C., and Grubman M.J. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 22 (2003) 268-279
41. Guzylack-Piriou L., Piersma S., McCullough K.C., and Summerfield A. Role of natural interferon-producing cells and T lymphocytes in porcine monocyte-derived dendritic cell maturation. Immunology 118 (2006) 78-87
42. Korst R.J., Mahtabifard A., Yamada R., and Crystal R.G. Effect of adenovirus gene transfer vectors on the immunologic functions of mouse dendritic cells. Mol Ther 5 (2002) 307-315
43. Miller G., Lahrs S., Shah A.B., and DeMatteo R.P. Optimization of dendritic cell maturation and gene transfer by recombinant adenovirus. Cancer Immunol Immunother 52 (2003) 347-358
44. Molinier-Frenkel V., Prévost-Blondel A., Hong S.S., Lengagne R., Boudaly S., Magnusson M.K., et al. The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain. J Biol Chem 278 (2003) 37175-37182
45. Schumacher L., Ribas A., Dissette V.B., McBride W.H., Mukherji B., Economou J.S., et al. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 27 (2004) 191-200
46. Basner-Tschakarjan E., Gaffal E., O'Keeffe M., Tormo D., Limmer A., Wagner H., et al. Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production. J Gene Med 8 (2006) 1300-1306
47. Morelli A.E., Larregina A.T., Ganster R.W., Zahorchak A.F., Plowey J.M., Takayama T., et al. Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol 74 (2000) 9617-9628
48. Salucci V., Lena A.M., Ciliberto G., Scarselli E., and La Monica N. Adenovirus transduction and culture conditions affect the immunogenicity of murine dendritic cells. Scand J Immunol 62 (2005) 206-217
49. Hirschowitz E.A., Weaver J.D., Hidalgo G.E., and Doherty D.E. Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Ther 7 (2000) 1112-1120
50. Bontkes H.J., Ruizendaal J.J., Schreurs M.W., Kramer D., Meijer C.J., and Hooijberg E. Antigen gene transfer to human plasmacytoid dendritic cells using recombinant adenovirus and vaccinia virus vectors. Cell Oncol 27 (2005) 175-182
51. Korokhov N., Noureddini S.C., Curiel D.T., Santegoets S.J., Scheper R.J., and de Gruijl T.D. A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. Mol Pharm 2 (2005) 218-223
52. Zhang Y., and Bergelson J.M. Adenovirus receptors. J Virol 79 (2005) 12125-12131
53. Rea D., Schagen F.H., Hoeben R.C., Mehtali M., Havenga M.J., Toes R.E., et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol 73 (1999) 10245-10253
54. Perreau M., Mennechet F., Serratrice N., Glasgow J.N., Curiel D.T., Wodrich H., et al. Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol 81 (2007) 3272-3284
55. Rea D., Havenga M.J., van Den Assem M., Sutmuller R.P., Lemckert A., Hoeben R.C., et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 166 (2001) 5236-5244
56. Loré K., Adams W.C., Havenga M.J., Precopio M.L., Holterman L., Goudsmit J., et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 179 (2007) 1721-1729
57. Hsu C., Boysen M., Gritton L.D., Frosst P.D., Nemerow G.R., and Von Seggern D.J. In vitro dendritic cell infection by pseudotyped adenoviral vectors does not correlate with their in vivo immunogenicity. Virology 332 (2005) 1-7
58. Huang S., Kamata T., Takada Y., Ruggeri Z.M., and Nemerow G.R. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol 70 (1996) 4502-4508
59. Wickham T.J., Tzeng E., Shears II L.L., Roelvink P.W., Li Y., Lee G.M., et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 71 (1997) 8221-8229
60. Wickham T.J., Mathias P., Cheresh D.A., and Nemerow G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73 (1993) 309-319
61. Mathias P., Wickham T., Moore M., and Nemerow G. Multiple adenovirus serotypes use alpha v integrins for infection. J Virol 68 (1994) 6811-6814
62. Worgall S., Busch A., Rivara M., Bonnyay D., Leopold P.L., Merritt R., et al. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol 78 (2004) 2572-2580
63. Dechecchi M.C., Tamanini A., Bonizzato A., and Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 268 (2000) 382-390
64. Hafenstein S., Palermo L.M., Kostyuchenko V.A., Xiao C., Morais M.C., Nelson C.D., et al. Asymmetric binding of transferrin receptor to parvovirus capsids. Proc Natl Acad Sci USA 104 (2007) 6585-6589
65. Rossmann M.G., He Y., and Kuhn R.J. Picornavirus-receptor interactions. Trends Microbiol 10 (2002) 324-331
66. Jackson T., Ellard F.M., Ghazaleh R.A., Brookes S.M., Blakemore W.E., Corteyn A.H., et al. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J Virol 70 (1996) 5282-5287
67. Sa-Carvalho D., Rieder E., Baxt B., Rodarte R., Tanuri A., and Mason P.W. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol 71 (1997) 5115-5123
68. Baranowski E., Ruiz-Jarabo C.M., Sevilla N., Andreu D., Beck E., and Domingo E. Cell recognition by foot-and-mouth disease virus that lacks the RGD integrin-binding motif: flexibility in aphthovirus receptor usage. J Virol 74 (2000) 1641-1647
69. Rigden R.C., Carrasco C.P., Summerfield A., and McCullough K.C. Macrophage phagocytosis of foot-and-mouth disease virus may create infectious carriers. Immunology 106 (2002) 537-548
70. Harwood L.J., Gerber H., Sobrino F., Summerfield A., and McCullough K.C. Dendritic cell internalisation of foot-and-mouth disease virus: influence of heparan sulphate binding on virus uptake and immune response induction. J Virol (2008)
71. Jackson T., Sheppard D., Denyer M., Blakemore W., and King A.M. The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus. J Virol 74 (2000) 4949-4956
72. Jackson T., Clark S., Berryman S., Burman A., Cambier S., Mu D., et al. Integrin alphavbeta8 functions as a receptor for foot-and-mouth disease virus: role of the beta-chain cytodomain in integrin-mediated infection. J Virol 78 (2004) 4533-4540
73. Berinstein A., Roivainen M., Hovi T., Mason P.W., and Baxt B. Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol 69 (1995) 2664-2666
74. Neff S., Sa-Carvalho D., Rieder E., Mason P.W., Blystone S.D., Brown E.J., et al. Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor. J Virol 72 (1998) 3587-3594
75. Enjuanes L.S.I., Alonso S., Escors D., and Zúñiga S. Coronavirus reverse genetics and development of vectors for gene expression. Curr Top Microbiol Immunol 287 (2005) 161-197
76. Riffault S., Carrat C., Besnardeau L., La Bonnardière C., and Charley B. In vivo induction of interferon-alpha in pig by non-infectious coronavirus: tissue localization and in situ phenotypic characterization of interferon-alpha-producing cells. J Gen Virol 78 (1997) 2483-2487
77. Riffault S., Carrat C., van Reeth K., Pensaert M., and Charley B. Interferon-alpha-producing cells are localized in gut-associated lymphoid tissues in transmissible gastroenteritis virus (TGEV) infected piglets. Vet Res 32 (2001) 71-79
78. Charley B., Riffault S., and Van Reeth K. Porcine innate and adaptative immune responses to influenza and coronavirus infections. Ann N Y Acad Sci 1081 (2006) 130-136
79. Baudoux P., Carrat C., Besnardeau L., Charley B., and Laude H. Coronavirus pseudoparticles formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes. J Virol 72 (1998) 8636-8643
80. Riffault S., Grosclaude J., Vayssier M., Laude H., and Charley B. Reconstituted coronavirus TGEV virosomes lose the virus ability to induce porcine interferon-alpha production. Vet Res 28 (1997) 105-114
81. Glück R., Mischler R., Brantschen S., Just M., Althaus B., and Cryz Jr. S.J. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 90 (1992) 2491-2495
82. Lambkin R., Oxford J.S., Bossuyt S., Mann A., Metcalfe I.C., Herzog C., et al. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. Vaccine 22 (2004) 4390-4396
83. Felnerova D., Viret J.F., Glück R., and Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 15 (2004) 518-529
84. Angel J., Chaperot L., Molens J.P., Mezin P., Amacker M., Cabral M.G., et al. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine 25 (2007) 3913-3921
85. Reading P.C., Miller J.L., and Anders E.M. Involvement of the mannose receptor in infection of macrophages by influenza virus. J Virol 74 (2000) 5190-5197
86. Santos L., Draves K.E., Boton M., Grewal P.K., Marth J.D., and Clark E.A. Dendritic cell-dependent inhibition of B cell proliferation requires CD22. J Immunol 180 (2008) 4561-4569
87. Videira P.A., Amado I.F., Crespo H.J., Alguero M.C., Dall'olio F., Cabral M.G., et al. Surface alpha2-3- and alpha2-6-sialylation of human monocytes and derived dendritic cells and its influence on endocytosis. Glycoconj J 25 (2008) 259-268
88. Aoki H., Sakoda Y., Jukuroki K., Takada A., Kida H., and Fukusho O. Induction of antibodies in mice by a recombinant baculovirus expressing pseudorabies virus glycoprotein B in mammalian cells. Vet Microbiol 68 (1999) 197-207
89. Manoutcharian K., Diaz-Orea A., Gevorkian G., Fragoso G., Acero G., Gonzalez E., et al. Recombinant bacteriophage-based multiepitope vaccine against Taenia solium pig cysticercosis. Vet Immunol Immunopathol 99 (2004) 11-24
90. Yang Y., Chen J., Li H., Wang Y., Xie Z., Wu M., et al. Porcine interleukin-2 gene encapsulated in chitosan nanoparticles enhances immune response of mice to piglet paratyphoid vaccine. Comp Immunol Microbiol Infect Dis 30 (2007) 19-32
91. Ren Z.J., Tian C.J., Zhu Q.S., Zhao M.Y., Xin A.G., Nie W.X., et al. Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice. Vaccine 26 (2008) 1471-1481
92. Lo-Man R., Rueda P., Sedlik C., Deriaud E., Casal I., and Leclerc C. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol 28 (1998) 1401-1407
93. Fenaux M., Opriessnig T., Halbur P.G., and Meng X.J. Immunogenicity and pathogenicity of chimeric infectious DNA clones of pathogenic porcine circovirus type 2 (PCV2) and nonpathogenic PCV1 in weanling pigs. J Virol 77 (2003) 11232-11243
94. Fenaux M., Opriessnig T., Halbur P.G., Elvinger F., and Meng X.J. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs. J Virol 78 (2004) 6297-6303
95. Pan Q., He K., and Huang K. Development of recombinant porcine parvovirus-like particles as an antigen carrier formed by the hybrid VP2 protein carrying immunoreactive epitope of porcine circovirus type 2. Vaccine (2008)
96. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. J Anat 189 (1996) 503-505
97. Ogris M., Brunner S., Schuller S., Kircheis R., and Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther 6 (1999) 595-605
98. Gu X.G., Schmitt M., Hiasa A., Nagata Y., Ikeda H., Sasaki Y., et al. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res 58 (1998) 3385-3390
99. Johansen P., Estevez F., Zurbriggen R., Merkle H.P., Gluck R., Corradin G., et al. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine 19 (2000) 1047-1054
100. Vajdy M., and O'Hagan D.T. Microparticles for intranasal immunization. Adv Drug Deliv Rev 51 (2001) 127-141
101. Cui Z., and Mumper R.J. The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses. Eur J Pharm Biopharm 55 (2003) 11-18
102. Katare Y.K., Panda A.K., Lalwani K., Haque I.U., and Ali M.M. Potentiation of immune response from polymer-entrapped antigen: toward development of single dose tetanus toxoid vaccine. Drug Deliv 10 (2003) 231-238
103. Locher C.P., Putnam D., Langer R., Witt S.A., Ashlock B.M., and Levy J.A. Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation. Immunol Lett 90 (2003) 67-70
104. Zhou S., Liao X., Li X., Deng X., and Li H. Poly-d,l-lactide-co-poly(ethylene glycol) microspheres as potential vaccine delivery systems. J Control Release 86 (2003) 195-205
105. Farokhzad O.C., Jon S., Khademhosseini A., Tran T.N., Lavan D.A., and Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64 (2004) 7668-7672
106. Chong C.S., Cao M., Wong W.W., Fischer K.P., Addison W.R., Kwon G.S., et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release 102 (2005) 85-99
107. Tobio M., Gref R., Sanchez A., Langer R., and Alonso M.J. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 15 (1998) 270-275
108. Eyles J.E., Bramwell V.W., Williamson E.D., and Alpar H.O. Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. Vaccine 19 (2001) 4732-4742
109. van der Lubben I.M., Kersten G., Fretz M.M., Beuvery C., Coos Verhoef J., and Junginger H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21 (2003) 1400-1408
110. Koping-Hoggard M., Sanchez A., and Alonso M.J. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines 4 (2005) 185-196
111. O'Hagan D.T., Singh M., and Ulmer J.B. Microparticle-based technologies for vaccines. Methods 40 (2006) 10-19
112. Zhao ZZ, Zhang HB, Chen Q, Su D, Xie Z, Wang YY, et al. Promotion of immunity of mice to Pasteurella multocida and hog cholera vaccine by pig interleukin-6 gene and CpG motifs. Comp Immunol Microbiol Infect Dis 2008, in press [available online 14 February 2008].
113. Fu M.L., Ying S.C., Wu M., Li H., Wu K.Y., Yang Y., et al. Regulating effects of novel CpG chitosan-nanoparticles on immune responses of mice to porcine paratyphoid vaccines. Biomed Environ Sci 19 (2006) 315-322
114. Macklin M.D., McCabe D., McGregor M.W., Neumann V., Meyer T., Callan R., et al. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J Virol 72 (1998) 1491-1496
115. Swain W.F., Macklin M.D., Neumann G., McCabe D.E., Drape R., Fuller J.T., et al. Manipulation of immune responses via particle-mediated polynucleotide vaccines. Behring Inst Mitt 98 (1997) 73-78
116. Kohli A.K., and Alpar H.O. Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. Int J Pharm 275 (2004) 13-17
117. Ceppi M., Ruggli N., Tache V., Gerber H., McCullough K.C., and Summerfield A. Double-stranded secondary structures on mRNA induce type I interferon (IFN alpha/beta) production and maturation of mRNA-transfected monocyte-derived dendritic cells. J Gene Med 7 (2005) 452-465
118. Paglia P., Medina E., Arioli I., Guzman C.A., and Colombo M.P. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 92 (1998) 3172-3176
119. Cochlovius B., Stassar M.J., Schreurs M.W., Benner A., and Adema G.J. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity. Immunol Lett 80 (2002) 89-96
120. Franco L.H., Wowk P.F., Silva C.L., Trombone A.P., Coelho-Castelo A.A., Oliver C., et al. A DNA vaccine against tuberculosis based on the 65 kDa heat-shock protein differentially activates human macrophages and dendritic cells. Genet Vaccines Ther 6 (2008) 3-13
121. Bot A., Stan A.C., Inaba K., Steinman R., and Bona C. Dendritic cells at a DNA vaccination site express the encoded influenza nucleoprotein and prime MHC class I-restricted cytolytic lymphocytes upon adoptive transfer. Int Immunol 12 (2000) 825-832
122. Watkins C., Hopkins J., and Harkiss G. Reporter gene expression in dendritic cells after gene gun administration of plasmid DNA. Vaccine 23 (2005) 4247-4256
123. Kutzler M.A., and Weiner D.B. Developing DNA vaccines that call to dendritic cells. J Clin Invest 114 (2004) 1241-1244
124. Spies B., Hochrein H., Vabulas M., Huster K., Busch D.H., Schmitz F., et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 171 (2003) 5908-5912
125. You Z., Huang X., Hester J., Toh H.C., and Chen S.Y. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 61 (2001) 3704-3711
126. Nchinda G., Kuroiwa J., Oks M., Trumpfheller C., Park C.G., Huang Y., et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 118 (2008) 1427-1436
127. Gu Q.L., Huang X., Ren W.H., Shen L., Liu B.Y., and Chen S.Y. Targeting hepatitis B virus antigens to dendritic cells by heat shock protein to improve DNA vaccine potency. World J Gastroenterol 13 (2007) 5911-5917
128. Lauterbach H., Gruber A., Ried C., Cheminay C., and Brocker T. Insufficient APC capacities of dendritic cells in gene gun-mediated DNA vaccination. J Immunol 176 (2006) 4600-4607
129. Porgador A., Irvine K.R., Iwasaki A., Barber B.H., Restifo N.P., and Germain R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 188 (1998) 1075-1082
130. Jilek S., Merkle H.P., and Walter E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 57 (2005) 377-390
131. Jilek S., Zurkaulen H., Pavlovic J., Merkle H.P., and Walter E. Transfection of a mouse dendritic cell line by plasmid DNA-loaded PLGA microparticles in vitro. Eur J Pharm Biopharm 58 (2004) 491-499
132. Walter E., and Merkle H.P. Microparticle-mediated transfection of non-phagocytic cells in vitro. J Drug Target 10 (2002) 11-21
133. Lunsford L., McKeever U., Eckstein V., and Hedley M.L. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle. J Drug Target 8 (2000) 39-50
134. Trombone A.P., Silva C.L., Almeida L.P., Rosada R.S., Lima K.M., Oliver C., et al. Tissue distribution of DNA-Hsp65/TDM-loaded PLGA microspheres and uptake by phagocytic cells. Genet Vaccines Ther 5 (2007) 9-16
135. Dincer Z., Jones S., and Haworth R. Preclinical safety assessment of a DNA vaccine using particle-mediated epidermal delivery in domestic pig, minipig and mouse. Exp Toxicol Pathol 57 (2006) 351-357
136. Gamvrellis A., Leong D., Hanley J.C., Xiang S.D., Mottram P., and Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol 82 (2004) 506-516
137. Ceppi M., de Bruin M.G., Seuberlich T., Balmelli C., Pascolo S., Ruggli N., et al. Identification of classical swine fever virus protein E2 as a target for cytotoxic T cells by using mRNA-transfected antigen-presenting cells. J Gen Virol 86 (2005) 2525-2534
138. Prabha S., Zhou W.Z., Panyam J., and Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm 244 (2002) 105-115
139. Panyam J., and Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55 (2003) 329-347
140. Crocker P.R. Siglecs in innate immunity. Curr Opin Pharmacol 5 (2005) 431-437
141. Crocker P.R., and Varki A. Siglecs in the immune system. Immunology 103 (2001) 137-145
142. Varki A., and Angata T. Siglecs-the major subfamily of I-type lectins. Glycobiology 16 (2006) 1R-27R
143. Zhang J., Raper A., Sugita N., Hingorani R., Salio M., Palmowski M.J., et al. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 107 (2006) 3600-3608
144. Lock K., Zhang J., Lu J., Lee S.H., and Crocker P.R. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells. Immunobiology 209 (2004) 199-207
145. Li N., Zhang W., Wan T., Zhang J., Chen T., Yu Y., et al. Cloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells. J Biol Chem 276 (2001) 28106-28112
146. Nicoll G., Ni J., Liu D., Klenerman P., Munday J., Dubock S., et al. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem 274 (1999) 34089-34095
147. Angata T., Tabuchi Y., Nakamura K., and Nakamura M. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology 17 (2007) 838-846
148. Bax M., Garcia-Vallejo J.J., Jang-Lee J., North S.J., Gilmartin T.J., Hernandez G., et al. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J Immunol 179 (2007) 8216-8224
149. Pyz E., Marshall A.S., Gordon S., and Brown G.D. C-type lectin-like receptors on myeloid cells. Ann Med 38 (2006) 242-251
150. Kretz-Rommel A., Qin F., Dakappagari N., Torensma R., Faas S., Wu D., et al. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother 30 (2007) 715-726
151. Pereira C.F., Torensma R., Hebeda K., Kretz-Rommel A., Faas S., Figdor C.G., et al. In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model. J Immunother 30 (2007) 705-714
152. Barondes S.H., Castronovo V., Cooper D.N., Cummings R.D., Drickamer K., Feizi T., et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 76 (1994) 597-598
153. Blasius A.L., and Colonna M. Sampling and signaling in plasmacytoid dendritic cells: the potential roles of Siglec-H. Trends Immunol 27 (2006) 255-260
154. Vanderheijden N., Delputte P.L., Favoreel H.W., Vandekerckhove J., Van Damme J., van Woensel P.A., et al. Involvement of sialoadhesin in entry of porcine reproductive and respiratory syndrome virus into porcine alveolar macrophages. J Virol 77 (2003) 8207-8215
155. Steeghs L., van Vliet S.J., Uronen-Hansson H., van Mourik A., Engering A., Sanchez-Hernandez M., et al. Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. Cell Microbiol 8 (2006) 316-325
156. Meyer S., van Liempt E., Imberty A., van Kooyk Y., Geyer H., Geyer R., et al. DC-SIGN mediates binding of dendritic cells to authentic pseudo-LewisY glycolipids of Schistosoma mansoni cercariae, the first parasite-specific ligand of DC-SIGN. J Biol Chem 280 (2005) 37349-37359
157. Sheng K.C., Pouniotis D.S., Wright M.D., Tang C.K., Lazoura E., Pietersz G.A., et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 118 (2006) 372-383
158. Apostolopoulos V., Pietersz G.A., Loveland B.E., Sandrin M.S., and McKenzie I.F. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 92 (1995) 10128-10132
159. Bessler W.G., and Jung G. Synthetic lipopeptides as novel adjuvants. Res Immunol 143 (1992) 548-553
160. Goethe R., Gonzales O.F., Lindner T., and Gerlach G.F. A novel strategy for protective Actinobacillus pleuropneumoniae subunit vaccines: detergent extraction of cultures induced by iron restriction. Vaccine 19 (2000) 966-975
161. Meens J., Selke M., and Gerlach G.F. Identification and immunological characterization of conserved Mycoplasma hyopneumoniae lipoproteins Mhp378 and Mhp651. Vet Microbiol 116 (2006) 85-95
162. Aranda J., Garrido M.E., Cortés P., Llagostera M., and Barbé J. Analysis of the protective capacity of three Streptococcus suis proteins induced under divalent-cation-limited conditions. Infect Immun 76 (2008) 1590-1598
163. Rau H., Revets H., Cornelis P., Titzmann A., Ruggli N., McCullough K.C., et al. Efficacy and functionality of lipoprotein OprI from Pseudomonas aeruginosa as adjuvant for a subunit vaccine against classical swine fever. Vaccine 24 (2006) 4757-4768
164. Moyle P.M., and Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem 15 (2008) 506-516
165. Cheng G., Zhao X., Yan W., Wang W., Zuo X., Huang K., et al. Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response. Vaccine 25 (2007) 5199-5208
166. O'Hagan D.T. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 1 (2001) 273-286
167. Singh M. Recent advances in vaccine adjuvants. Pharm Res 19 (2002) 715-728
168. O'Hagan D.T., and Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2 (2003) 269-283
169. Moyle P.M., McGeary R.P., Blanchfield J.T., and Toth I. Mucosal immunisation: adjuvants and delivery systems. Curr Drug Deliv 1 (2004) 385-396
170. Patel G.B., and Chen W. Archaeosome immunostimulatory vaccine delivery system. Curr Drug Deliv 2 4 (2005) 407-421
171. Christensen D., Korsholm K.S., Rosenkrands I., Lindenström T., Andersen P., and Agger E.M. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 6 (2007) 785-796
172. Allsopp C.E., Plebanski M., Gilbert S., Sinden R.E., Harris S., Frankel G., et al. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol 26 (1996) 1951-1959
173. Boato F., Thomas R.M., Ghasparian A., Freund-Renard A., Moehle K., and Robinson J.A. Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system. Angew Chem Int Ed Engl 46 (2007) 9015-9018
174. Nam J.H., Cha S.L., and Cho H.W. Immunogenicity of a recombinant MVA and a DNA vaccine for Japanese encephalitis virus in swine. Microbiol Immunol 46 (2002) 23-28
175. Konishi E., Pincus S., Paoletti E., Laegreid W.W., Shope R.E., and Mason P.W. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology 190 (1992) 454-458
176. Murata H., Britton P., Kaeffer B., Aynaud J.M., Chevaleyre C., and Salmon H. Specific cytotoxic lymphocyte response in swine against structural proteins of transmissible gastro-enteritis virus: a study using lymphoblastoid cell line and recombinant vaccinia virus. Vet Res 29 (1998) 467-474
177. Ma M., Jin N., Shen G., Zhu G., Liu H.J., Zheng M., et al. Immune responses of swine inoculated with a recombinant fowlpox virus co-expressing P12A and 3C of FMDV and swine IL-18. Vet Immunol Immunopathol 121 (2008) 1-7
178. Shen G., Jin N., Ma M., Jin K., Zheng M., Zhuang T., et al. Immune responses of pigs inoculated with a recombinant fowlpox virus coexpressing GP5/GP3 of porcine reproductive and respiratory syndrome virus and swine IL-18. Vaccine 25 (2007) 4193-4202
179. Voigt H., Merant C., Wienhold D., Braun A., Hutet E., Le Potier M.F., et al. Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2). Vaccine 25 (2007) 5915-5926
180. Fischer T., Planz O., Stitz L., and Rziha H.J. Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice. J Virol 77 (2003) 9312-9323
181. Büttner M., Czerny C.P., Lehner K.H., and Wertz K. Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs. Vet Immunol Immunopathol 46 (1995) 237-250
182. He Y., Qian P., Zhang K., Yao Q., Wang D., Xu Z., et al. Construction and immune response characterization of a recombinant pseudorabies virus co-expressing capsid precursor protein (P1) and a multiepitope peptide of foot-and-mouth disease virus in swine. Virus Genes 36 (2008) 393-400
183. Qian P., Li X.M., Jin M.L., Peng G.Q., and Chen H.C. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine. Vaccine 22 (2004) 2129-2136
184. Hong Q., Qian P., Li X.M., Yu X.L., and Chen H.C. A recombinant pseudorabies virus co-expressing capsid proteins precursor P1-2A of FMDV and VP2 protein of porcine parvovirus: a trivalent vaccine candidate. Biotechnol Lett 29 (2007) 1677-1683
185. Xu G., Xu X., Li Z., He Q., Wu B., Sun S., et al. Construction of recombinant pseudorabies virus expressing NS1 protein of Japanese encephalitis (SA14-14-2) virus and its safety and immunogenicity. Vaccine 22 (2004) 1846-1853
186. Song Y., Jin M., Zhang S., Xu X., Xiao S., Cao S., et al. Generation and immunogenicity of a recombinant pseudorabies virus expressing cap protein of porcine circovirus type 2. Vet Microbiol 119 (2007) 97-104
187. Ju C., Fan H., Tan Y., Liu Z., Xi X., Cao S., et al. Immunogenicity of a recombinant pseudorabies virus expressing ORF1-ORF2 fusion protein of porcine circovirus type 2. Vet Microbiol 109 (2005) 179-190
188. Jiang Y., Fang L., Xiao S., Zhang H., Pan Y., Luo R., et al. Immunogenicity and protective efficacy of recombinant pseudorabies virus expressing the two major membrane-associated proteins of porcine reproductive and respiratory syndrome virus. Vaccine 25 (2007) 547-560
189. Jiang Y.B., Fang L.R., Xiao S.B., Zhang H., and Chen H.C. Construction and immunogenicity of recombinant pseudorabies virus expressing the modified GP5m protein of porcine reproduction and respiratory syndrome virus. Sheng Wu Gong Cheng Xue Bao 21 (2005) 858-864
190. Qiu H.J., Tian Z.J., Tong G.Z., Zhou Y.J., Ni J.Q., Luo Y.Z., et al. Protective immunity induced by a recombinant pseudorabies virus expressing the GP5 of porcine reproductive and respiratory syndrome virus in piglets. Vet Immunol Immunopathol 106 (2005) 309-319
191. Tian Z.J., Qiu H.J., Ni J.Q., Zhou Y.J., Cai X.H., Zhou G.H., et al. Construction and characterization of a recombinant pseudorabies virus expressing porcine reproductive and respiratory syndrome virus GP5. Yi Chuan Xue Bao 32 (2005) 1248-1255
192. Shiau A.L., Liu C.W., Wang S.Y., Tsai C.Y., and Wu C.L. A simple selection system for construction of recombinant gD-negative pseudorabies virus as a vaccine vector. Vaccine 20 (2002) 1186-1195
193. Tian Z.J., Zhou G.H., Zheng B.L., Qiu H.J., Ni J.Q., Yang H.L., et al. A recombinant pseudorabies virus encoding the HA gene from H3N2 subtype swine influenza virus protects mice from virulent challenge. Vet Immunol Immunopathol 111 (2006) 211-218
194. Yin J., Ren X., Tian Z., and Li Y. Assembly of pseudorabies virus genome-based transfer vehicle carrying major antigen sites of S gene of transmissible gastroenteritis virus: potential perspective for developing live vector vaccines. Biologicals 35 (2007) 55-61
195. Reddy P.S., Idamakanti N., Hyun B.H., Tikoo S.K., and Babiuk L.A. Development of porcine adenovirus-3 as an expression vector. J Gen Virol 80 (1999) 563-570
196. Hammond J.M., Jansen E.S., Morrissy C.J., Hodgson A.L., and Johnson M.A. Protection of pigs against 'in contact' challenge with classical swine fever following oral or subcutaneous vaccination with a recombinant porcine adenovirus. Virus Res 97 (2003) 151-157
197. Hammond J.M., Jansen E.S., Morrissy C.J., Williamson M.M., Hodgson A.L., and Johnson M.A. Oral and sub-cutaneous vaccination of commercial pigs with a recombinant porcine adenovirus expressing the classical swine fever virus gp55 gene. Arch Virol 146 (2001) 1787-1793
198. Liu Y., Hu R., Zhang S., Zhang F., Li Z., Wei X., et al. Expression of the foot-and-mouth disease virus VP1 protein using a replication-competent recombinant canine adenovirus type 2 elicits a humoral antibody response in a porcine model. Viral Immunol 19 (2006) 202-209
199. Mayr G.A., Chinsangaram J., and Grubman M.J. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 263 (1999) 496-506
200. Okamba F.R., Moreau E., Cheikh Saad Bouh K., Gagnon C.A., Massie B., and Arella M. Immune responses induced by replication-defective adenovirus expressing the C-terminal portion of the Mycoplasma hyopneumoniae P97 adhesin. Clin Vaccine Immunol 14 (2007) 767-774
201. Wang X., Jiang P., Li Y., Jiang W., and Dong X. Protection of pigs against post-weaning multisystemic wasting syndrome by a recombinant adenovirus expressing the capsid protein of porcine circovirus type 2. Vet Microbiol 121 (2007) 215-224
202. Wang X., Jiang W., Jiang P., Li Y., Feng Z., and Xu J. Construction and immunogenicity of recombinant adenovirus expressing the capsid protein of porcine circovirus 2 (PCV2) in mice. Vaccine 24 (2006) 3374-3380
203. Jiang W., Jiang P., Li Y., Wang X., and Du Y. Analysis of immunogenicity of minor envelope protein GP3 of porcine reproductive and respiratory syndrome virus in mice. Virus Genes 35 (2007) 695-704
204. Jiang W., Jiang P., Li Y., Tang J., Wang X., and Ma S. Recombinant adenovirus expressing GP5 and M fusion proteins of porcine reproductive and respiratory syndrome virus induce both humoral and cell-mediated immune responses in mice. Vet Immunol Immunopathol 113 (2006) 169-180
205. Callebaut P., Enjuanes L., and Pensaert M. An adenovirus recombinant expressing the spike glycoprotein of porcine respiratory coronavirus is immunogenic in swine. J Gen Virol 77 (1996) 309-313
206. Hammond J.M., Jansen E.S., Morrissy C.J., van der Heide B., Goff W.V., Williamson M.M., et al. Vaccination of pigs with a recombinant porcine adenovirus expressing the gD gene from pseudorabies virus. Vaccine 19 (2001) 3752-3758
207. Adam M., Lepottier M.F., and Eloit M. Vaccination of pigs with replication-defective adenovirus vectored vaccines: the example of pseudorabies. Vet Microbiol 42 (1994) 205-215
208. Wesley R.D. Overcoming maternal antibody interference by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of swine influenza virus. Vet Microbiol 118 (2006) 67-75
209. Wesley R.D., and Lager K.M. Evaluation of a recombinant human adenovirus-5 vaccine administered via needle-free device and intramuscular injection for vaccination of pigs against swine influenza virus. Am J Vet Res 66 (2005) 1943-1947
210. Tang M., Harp J.A., and Wesley R.D. Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2). Arch Virol 147 (2002) 2125-2141
211. Yang C.D., Liao J.T., Lai C.Y., Jong M.H., Liang C.M., Lin Y.L., et al. Induction of protective immunity in swine by recombinant bamboo mosaic virus expressing foot-and-mouth disease virus epitopes. BMC Biotechnol 7 (2007) 62
212. Wang Y., Liang Y., Han J., Burkhart K.M., Vaughn E.M., Roof M.B., et al. Attenuation of porcine reproductive and respiratory syndrome virus strain MN184 using chimeric construction with vaccine sequence. Virology 371 (2008) 418-429
213. Singh M., Chakrapani A., and O'Hagan D.T. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 6 (2007) 797-808
214. Vyas S.P., and Gupta P.N. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev Vaccines 6 (2007) 401-418
215. Davis S.S. The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine 24 (2006) 7-10
216. Azad N., and Rojanasakul Y. Vaccine delivery-current trends and future. Curr Drug Deliv 3 (2006) 137-146
217. Singh M., Kazzaz J., Ugozzoli M., Malyala P., Chesko J., and O'Hagan D.T. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv 3 (2006) 115-120
218. Jiang W., Gupta R.K., Deshpande M.C., and Schwendeman S.P. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 57 (2005) 391-410
219. Eyles J.E., Carpenter Z.C., Alpar H.O., and Williamson E.D. Immunological aspects of polymer microsphere vaccine delivery systems. J Drug Target 11 (2003) 509-514
220. Brayden D.J., and Baird A.W. Microparticle vaccine approaches to stimulate mucosal immunisation. Microbes Infect 3 (2001) 867-876
221. van der Lubben I.M., Verhoef J.C., Borchard G., and Junginger H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 14 (2001) 201-207
222. Torché A.M., Le Dimna M., Le Corre P., Mesplède A., Le Gal S., Cariolet R., et al. Immune responses after local administration of IgY loaded-PLGA microspheres in gut-associated lymphoid tissue in pigs. Vet Immunol Immunopathol 109 (2006) 209-217
223. Dawson M., Krauland E., Wirtz D., and Hanes J. Transport of polymeric nanoparticle gene carriers in gastric mucus. Biotechnol Prog 20 (2004) 851-857
224. Liao C.W., Chiou H.Y., Yeh K.S., Chen J.R., and Weng C.N. Oral immunization using formalin-inactivated Actinobacillus pleuropneumoniae antigens entrapped in microspheres with aqueous dispersion polymers prepared using a co-spray drying process. Prev Vet Med 61 (2003) 1-15
225. Osth K., Strindelius L., Larhed A., Ahlander A., Roomans G.M., Sjöholm I., et al. Uptake of ovalbumin-conjugated starch microparticles by pig respiratory nasal mucosa in vitro. J Drug Target 11 (2003) 75-82
226. Lin J.H., Weng C.N., Liao C.W., Yeh K.S., and Pan M.J. Protective effects of oral microencapsulated Mycoplasma hyopneumoniae vaccine prepared by co-spray drying method. J Vet Med Sci 65 (2003) 69-74
227. Aucouturier J., Deville S., Perret C., Vallée I., and Boireau P. Assessment of efficacy and safety of various adjuvant formulations with a total soluble extract of Trichinella spiralis. Parasite 8 (2001) 126-132
228. Singh M., Briones M., and O'Hagan D.T. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 70 (2001) 267-276
229. Beier R., and Gebert A. Kinetics of particle uptake in the domes of Peyer's patches. Am J Physiol 275 (1998) G130-G137
230. Weng C.N., Tzan Y.L., Liu S.D., Lin S.Y., and Lee C.J. Protective effects of an oral microencapsulated Mycoplasma hyopneumoniae vaccine against experimental infection in pigs. Res Vet Sci 3 1 (1992) 42-46
231. Gou M., Dai M., Li X., Yang L., Huang M., Wang Y., et al. Preparation of mannan modified anionic PCL-PEG-PCL nanoparticles at one-step for bFGF antigen delivery to improve humoral immunity. Colloids Surf B Biointerfaces (2008)
232. Lu Y., Kawakami S., Yamashita F., and Hashida M. Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials 28 (2007) 3255-3262
233. Hattori Y., Kawakami S., Lu Y., Nakamura K., Yamashita F., and Hashida M. Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration. J Gene Med 8 (2006) 824-834
234. Cui Z., and Mumper R.J. Topical immunization using nanoengineered genetic vaccines. J Control Release 81 (2002) 173-184